Clinical Trial Update: The Effects of Omega-3 Fatty Acid (OMACOR) on the Low-density Lipoprotein (LDL) Sub-fraction in Type 2 Diabetic Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating OMACOR (omega-3 fatty acid) on LDL sub-fractions in adults with type 2 diabetes and dyslipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hypertriglyceridemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Omacor (omega-3-acid ethyl esters)

Snippet

Sponsor: Inje University | Conditions: Diabetes Mellitus, Type 2, Hypercholesterolemia | Phase 4 | Status: UNKNOWN